avkАрхивъ внутренней медициныThe Russian Archives of Internal Medicine2226-67042411-6564“SINAPS” LLC10.20514/2226-6704-2016-6-3-19-24avk-528Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESНОВЫЕ ВОЗМОЖНОСТИ В ТЕРАПИИ СЕРДЕЧНО-СОСУДИСТОЙ ПАТОЛОГИИ С ИСПОЛЬЗОВАНИЕМ КОЛХИЦИНАNEW POSSIBILITIES IN THE TREATMENT OF CARDIOVASCULAR DISEASE USING COLCHICINEВатутинН. Т.VatutinM. T.

кафедра госпитальной терапии,

г. Донецк

department of hospital therapy,

Donetsk

СмирноваА. С.SmyrnovaG. S.

кафедра госпитальной терапии,

г. Донецк

department of hospital therapy,

Donetsk

a.smyrnova@mail.ruЦеликоваЕ. О.TselikovaE. O.

кафедра госпитальной терапии,

г. Донецк

department of hospital therapy,

Donetsk

Донецкий национальный медицинский университет им. М. Горького; Институт неотложной и восстановительной хирургии им. В.К. ГусакаУкраинаM. Gorky Donetsk National Medical University; V.K. Gusak Institute of Urgent and Recovery SurgeryUkraineДонецкий национальный медицинский университет им. М. ГорькогоУкраинаM. Gorky Donetsk National Medical UniversityUkraine201610062016631924Copyright © Ватутин Н.Т., Смирнова А.С., Целикова Е.О., 20162016Ватутин Н.Т., Смирнова А.С., Целикова Е.О.Vatutin M.T., Smyrnova G.S., Tselikova E.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medarhive.ru/jour/article/view/528

В представленном обзоре литературы отражены вопросы фармакологических свойств и механизма действия колхицина. Авторами предоставлены результаты ряда научных работ, посвященных изучению эффекта колхицина на течение сердечно-сосудистых заболеваний.

The present review of the literature reflects issues of the colchicine’s pharmacological properties and mechanism of action. The authors provided the results of a number of scientific studies dedicated to the effects of colchicine on the cardiovascular pathology.

колхицинсердечно-сосудистые заболеванияcolchicinecardiovascular diseaseReferencesNidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013; 61: 404-41. doi:10.1016/j.jacc.2012.10.027.Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 2013; 61: 404-41.Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011; 12:103. doi:10.1186/1471-2474-12-103.Primatesta P., Plana E., Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011; 12: 103.Gow P. Treating Gout in Patients With Comorbidities. Int J Clin Rheumatol. 2011; 6: 625-633. doi:10.2217/ijr.11.63Gow P. Treating Gout in Patients With Comorbidities. Int. J. Clin. Rheumatol. 2011; 6: 625-633.Deftereos S, Giannopoulos G, Papoutsidakis N. Colchicine and the Heart: Pushing the Envelope. J Am Coll Cardiol. 2013; 62(20): 1817-1825. doi:10.1016/j.jacc.2013.08.726.Deftereos S., Giannopoulos G., Papoutsidakis N. Colchicine and the Heart: Pushing the Envelope. J Am. Coll. Cardiol. 2013; 62(20): 1817-1825.Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol. 2008; 153(6): 1288-1295. doi:10.1038/bjp.2008.20.Chia E.W., Grainger R., Harper J.L. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br. J. Pharmacol. 2008; 153 (6): 1288-1295.Алекберова З.С., Барскова В.Г. Колхицин в ревматологии — вчера и сегодня. Будет ли завтра? Современная ревматология. 2010; 4(2):25-29. doi:10.14412/1996-7012-2010-598.Alekberova Z.S., Barskova V.G. Colchicine in rheumatology: yesterday and today. Will there be tomorrow? Sovremennaya revmatologiya. 2010; 4 (2): 25-29. (In Russ.).Marques-da-Silva C, Chaves M, Castro N, Coutinho-Silva R, Guimaraes M. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br J Pharmacol. 2011; 163(5): 912-926. doi:10.1111/j.1476-5381.2011.01254.x.Marques-da-Silva C., Chaves M., Castro N. et al. Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7 receptor-expressing cells: implications for its therapeutic action. Br. J. Pharmacol. 2011; 163 (5): 912-926.Майданник В.Г. Современные аспекты синдрома периодической лихорадки с афтозным стоматитом, фарингитом и шейным лимфаденитом (синдром Маршалла) у детей. Международный журнал педиатрии, акушерства и гинекологии. 2013; 3: 63-74.Maidannyk V.G. Modern aspects of periodic fever with aphthous stomatitis, pharyngitis and cervical adenitis (Marshall's syndrome) in children. Mezhdunarodnyi zhurnal pediatrii, akusherstva i ginekologii. 2013; 3: 63-74. (In Russ.).Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995; 96(2): 994-1002. doi:10.1172/JCI118147.Cronstein B.N., Molad Y., Reibman J. et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J. Clin. Invest. 1995; 96 (2): 994-1002.Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of Action of Colchicine in the Treatment of Gout. Clin Ther. 2014; 36(10): 1465-1479. doi:10.1016/j.clinthera.2014.07.017.Dalbeth N., Lauterio T.J., Wolfe H.R. Mechanism of Action of Colchicine in the Treatment of Gout. Clin. Ther. 2014; 36 (10): 1465-1479.Cotran RS, Mayadas-Norton T. Endothelial adhesion molecules in health and disease. Pathol Biol (Paris). 1998; 46(3): 164-70.Cotran R.S., Mayadas-Norton T. Endothelial adhesion molecules in health and disease. Pathol. Biol. (Paris). 1998; 46 (3): 164-70.Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, Akira S. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013; 14: 454–460. doi:10.1038/ni.2550.Misawa T., Takahama M., Kozaki T. et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 2013; 14: 454–460.Wang Y, Viollet B, Terkeltaub R, Liu-Bryan R. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann Rheum Dis. 2016; 75(1): 286-94. doi: 10.1136/annrheumdis-2014-206074.Wang Y, Viollet B, Terkeltaub R, Liu-Bryan R. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann Rheum Dis. 2014. [Epub ahead of print]. doi:10.1136/annrheumdis-2014-206074.Preau S, Montaigne D, Modine T, Fayad G, Koussa M, Tardivel M, Durocher A, Saulnier F, Marechal X, Neviere R. Macrophage migration inhibitory factor induces contractile and mitochondria dysfunction by altering cytoskeleton network in the human heart. Crit Care Med. 2013; 41(7): 125-33. doi:10.1097/CCM.0b013e31827c0d8cPreau S., Montaigne D., Modine T. et al. Macrophage migration inhibitory factor induces contractile and mitochondria dysfunction by altering cytoskeleton network in the human heart. Crit. Care Med. 2013; 41 (7): 125-33.Menche D, Israel A, Karpatkin S. Platelets and Microtubules. Effect of colchicine and D2O on platelet aggregation and release induced by calcium ionophore A23187. J Clin Invest. 1980; 66(2): 284–291.Menche D., Israel A., Karpatkin S. Platelets and Microtubules. Effect of colchicine and D2O on platelet aggregation and release induced by calcium ionophore A23187. J. Clin. Invest. 1980; 66 (2): 284–291.Micha Levy, Amiram Eldor’, Ester Zylber-Katz, Marcel Ellakim. The effect of long-term colchicine therapy in patients with recurrent polyserositis on the capacity of blood platelets to synthesize thromboxane A2. Br J Сlin Pharmac. 1983; 16: 191-194.Levy M., Eldor A., Zylber-Katz E., Ellakim M. The effect of long-term colchicine therapy in patients with recurrent polyserositis on the capacity of blood platelets to synthesize thromboxane A2. Br. J. Сlin. Pharmac. 1983;16:191-194.Yun-Jin Jung, Jennifer S. Isaacs, Sunmin Lee, Jane Trepel, Len Neckers. Microtubule Disruption Utilizes an NFB-dependent Pathway to Stabilize HIF-1 Protein. The journal of biological chemistry. 2003; 278(9): 7445–7452. doi:10.1074/jbc.M209804200.Jung Y., Isaacs J.S., Lee S. et al. Microtubule Disruption Utilizes an NFB-dependent Pathway to Stabilize HIF-1 Protein. The journal of biological chemistry. 2003; 278 (9): 7445–7452.Серебровская ТВ. Гипоксия+индуцибельный фактор: роль в патофизиологии дыхания (обзор). Український пульмонологічний журнал. 2005; 3: 77-81.Serebrovskaya TV. Gipoksiya+indutsibel'nyi faktor: rol' v patofiziologii dykhaniya (obzor). Ukraїns'kii pul'monologіchnii zhurnal. 2005; 3: 77-81. (In Russ.).Щербак НС, Галагудза ММ, Шляхто ЕВ. Роль индуцируемого гипоксией фактора-1 (HIF-1) в реализации цитопротективного эффекта ишемического и фармакологического посткондиционирования. Российский кардиологический журнал. 2014; 11(115): 70-75. doi:10.15829/1560-4071-2014-11-70-75.Shcherbak N.S., Galagudza M.M., Shlyakhto E.V. Rol' indutsiruemogo gipoksiei faktora-1 (HIF-1) v realizatsii tsitoprotektivnogo effekta ishemicheskogo i farmakologicheskogo postkonditsionirovaniya. Rossiiskii kardiologicheskii zhurnal. 2014; 11 (115): 70-75. (In Russ.).Maisch B, Seferovic Р, Ristic A. Erbel R, Rienmüller R, Adler Y, Tomkowski WZ, Thiene G, Yacoub MH. Guidelines on the diagnosis and management of pericardial diseases. Eur Heart J. 2004; 25(7): 587-610.Maisch B., Seferovic Р., Ristic A. et al. Guidelines on the diagnosis and management of pericardial diseases. Eur. Heart J. 2004; 25 (7): 587-610.Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, Moratti M, Gaschino G, Giammaria M, Ghisio A, Belli R, Trinchero R. Colchicine in Addition to Conventional Therapy for Acute Pericarditis. Results of the COlchicine for acute PEricarditis (COPE) Trial. Circulation. 2005; 112: 2012-2016.Imazio M., Bobbio M., Cecchi E. et al. Colchicine in Addition to Conventional Therapy for Acute Pericarditis. Results of the COlchicine for acute PEricarditis (COPE) Trial. Circulation. 2005; 112: 2012-2016.Imazio M., Bobbio M., Cecchi E, Demarie D, Pomari F, Moratti M, Ghisio A, Belli R, Trinchero R. Colchicine as First-Choice Therapy for Recurrent Pericarditis. Results of the CORE (COlchicine for REcurrent pericarditis) Trial. Arch Intern Med. 2005; 165: 1987-1991.Imazio M., Bobbio M., Cecchi E. et al. Colchicine as First-Choice Therapy for Recurrent Pericarditis. Results of the CORE (COlchicine for REcurrent pericarditis) Trial. Arch. Intern. Med. 2005; 165: 1987-1991.Imazio M, Brucato A, Cemin R. Ferrua S, Belli R, Maestroni S, Trinchero R, Spodick DH, Adler Y. Colchicine for recurrent pericarditis (CORP): а randomized trial. Ann Intern Med. 2011; 155(7): 409-414. doi:10.7326/0003-4819-155-7-201110040-00359.Imazio M., Brucato A., Cemin R. et al. Colchicine for recurrent pericarditis (CORP): а randomized trial. Ann. Intern. Med. 2011; 155 (7): 409-414.Imazio M, Trinchero R, Brucato A, Rovere ME, Gandino A, Cemin R, Ferrua S, Maestroni S, Zingarelli E, Barosi A, Simon C, Sansone F, Patrini D, Vitali E, Ferrazzi P, Spodick DH, Adler Y. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010; 31(22): 2749-54. doi:10.1093/eurheartj/ehq319.Imazio M., Trinchero R., Brucato A. et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur. Heart J. 2010; 31 (22): 2749-54.Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013; 61: 404-410. doi:10.1016/j.jacc.2012.10.027.Nidorf S.M., Eikelboom J.W., Budgeon C.A., Thompson P.L. Low-dose colchicine for secondary prevention of cardiovascular disease. J. Am. Coll. Cardiol. 2013; 61: 404-410.Frangogiannis NG. Regulation of the Inflammatory Response in Cardiac Repair. Circ Res. 2012; 110: 159-173. doi: 10.1161/CIRCRESAHA.111.243162.Frangogiannis N.G. Regulation of the Inflammatory Response in Cardiac Repair. Circ. Res. 2012; 110: 159-173.Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodeling. Nat Rev Cardiol. 2014; 11(5): 255–265. doi:10.1038/nrcardio.2014.28.Frangogiannis N.G. The inflammatory response in myocardial injury, repair, and remodeling. Nat. Rev. Cardiol. 2014; 11 (5): 255–265.Folmes CD, Clanachan AS, Lopaschuk GD. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr Atheroscler Rep. 2005; 7(1): 63-70.Folmes C.D., Clanachan A.S., Lopaschuk G.D. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr. Atheroscler. Rep. 2005; 7 (1): 63-70.Парнес ЕЯ, Гаврилов СА. О возможностях использования лорноксикама у больных инфарктом миокарда с подъемом сегмента ST. Кардиология. 2011; 3: 23-28.Parnes E.Y., Gavrilov S.A. O vozmozhnostyakh ispol'zovaniya lornoksikama u bol'nykh infarktom miokarda s pod"emom segmenta ST. Kardiologiya. 2011; 3: 23-28. (In Russ.).Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos J, Alexopoulos D, Pyrgakis V,Cleman MW, Manolis AS, Tousoulis D, Lekakis J. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015; 132(15): 1395-403. doi: 10.1161/CIRCULATIONAHA.115.017611.Deftereos S., Giannopoulos G., Angelidis C. et al. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015; 132 (15): 1395-403.Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, Cronstein BN, Sedlis SP, Pillinger MH. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012; 39(7): 1458-64. doi:10.3899/jrheum.111533.Crittenden D.B,, Lehmann R.A., Schneck L. et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J. Rheumatol. 2012; 39 (7): 1458-64.Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolysis. 2012; 33: 88–94. doi: 10.1007/s11239-011-0637-y.Raju N.C., Yi Q., Nidorf M. et al. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J. Thromb. Thrombolysis. 2012; 33: 88–94.Узун ДЮ. Связь системного воспаления и постимплантационной фибрилляции предсердий у больных пожилого возраста с имплантированным двухкамерным водителем сердечного ритма. Современная медицина: актуальные вопросы. 2015; 1(37): 1-7.Uzun D. Assosiation system inflammation and post-implantation atrial fibrillation in eldery patients with implanted double chamber cardiac pacemaker. Sovremennaya meditsina: aktual'nye voprosy. 2015; 1 (37): 1-7. (In Russ.).Deftereos S, Giannopoulos G, Kossyvakis C, Efremidis M, Panagopoulou V, Kaoukis A, Raisakis K, Bouras G, Angelidis C, Theodorakis A, Driva M, Doudoumis K, Pyrgakis V, Stefanadis C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol. 2012; 60: 1790-6. doi: 10.1016/j.jacc.2012.07.031.Deftereos S., Giannopoulos G., Kossyvakis C. et al. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J. Am. Coll. Cardiol. 2012; 60: 1790-1796.Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, Bala R, Dixit S, Riley M, Hutchinson MD, Cooper J, Russo AM, Verdino R, Gerstenfeld EP. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol. 2011; 4(1): 11-4. doi:10.1161/CIRCEP.110.955393.Leong-Sit P., Roux J.F., Zado E. et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ. Arrhythm. Electrophysiol. 2011; 4 (1): 11-14.Kamkin A, Kirischuk S, Kiseleva I. Single mechano-gated channels activated by mechanical deformation of acutely isolated cardiac fibroblasts from rats. Acta Physiol (Oxf). 2010; 199: 277-92. doi:10.1111/j.1748-1716.2010.02086.x.Kamkin A., Kirischuk S., Kiseleva I. Single mechano-gated channels activated by mechanical deformation of acutely isolated cardiac fibroblasts from rats. Acta. Physiol. (Oxf). 2010; 199: 277-292Kamkin A, Kiseleva I, Wagner KD, Scholz H, Theres H, Kazanski V, Lozinsky I, Günther J, Isenberg G. Mechanically induced potentials in rat atrial fibroblasts depend on actin and tubulin polymerisation. Pflugers Arch. 2001; 442: 487-97. 47.Kamkin A., Kiseleva I., Wagner K.D. et al. Mechanically induced potentials in rat atrial fibroblasts depend on actin and tubulin polymerisation. Pflugers. Arch. 2001; 442: 487-497.Imazio M, Brucato A, Ferrazzi P, Rovere ME, Gandino A, Cemin R, Ferrua S, Belli R, Maestroni S, Simon C, Zingarelli E, Barosi A, Sansone F, Patrini D, Vitali E, Trinchero R, Spodick DH, Adler Y. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011; 124: 2290-5. doi:10.1161/CIRCULATIONAHA.111.026153.Imazio M., Brucato A., Ferrazzi P. et al. Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy. Circulation. 2011; 124: 2290-2295.Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, Caforio AL, Cemin R, Chirillo F, Comoglio C, Cugola D, Cumetti D, Dyrda O, Ferrua S, Finkelstein Y, Flocco R, Gandino A, Hoit B, Innocente F, Maestroni S, Musumeci F, Oh J, Pergolini A, Polizzi V, Ristic A, Simon C, Spodick DH, Tarzia V, Trimboli S, Valenti A, Belli R, Gaita F. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014; 312(10): 1016-23. doi:10.1001/jama.2014.11026.Imazio M., Brucato A., Ferrazzi P. et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014; 312 (10): 1016-1023.Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2011; 9(1): 53-62. doi:10.1038/nrcardio.2011.132.Jukema J.W., Verschuren J.J., Ahmed T.A., Quax P.H. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat. Rev. Cardiol. 2011; 9 (1): 53-62.Katsaros KM, Kastl SP, Zorn G. Increased Restenosis Rate After Implantation of Drug-Eluting Stents in Patients With Elevated Serum Activity of Matrix Metalloproteinase-2 and -9. J Am Coll Cardiol Intv. 2010; 3(1): 90-97.Katsaros K.M., Kastl S.P., Zorn G. Increased Restenosis Rate After Implantation of Drug-Eluting Stents in Patients With Elevated Serum Activity of Matrix Metalloproteinase-2 and -9. J. Am. Coll. Cardiol. Intv. 2010; 3 (1): 90-97.O’Keefe JH Jr., McCallister BD, Bateman TM. Ineffectiveness of colchicine for the prevention of restenosis. J Am Coll Cardiol. 1992; 19(7): 1597-600.O’Keefe J.H. Jr., McCallister B.D., Bateman T.M. Ineffectiveness of colchicine for the prevention of restenosis. J. Am. Coll. Cardiol. 1992; 19 (7): 1597-600.Freed M, Safian RD, O’Neill WW. Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1995; 76: 1185-8.Freed M., Safian R.D., O’Neill W.W. Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Am. J. Cardiol. 1995; 76: 1185-1188.Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V, Driva M, Hahalis G, Pyrgakis V, Alexopoulos D, Manolis AS, Stefanadis C, Cleman MW. Colchicine treatment for prevention of bare-metal stent restenosis in diabetics. J Am Coll Cardiol. 2013; 61: 1679-85. doi:10.1016/j.jacc.2013.01.055.Deftereos S., Giannopoulos G., Raisakis K. et al. Colchicine treatment for prevention of bare-metal stent restenosis in diabetics. J. Am. Coll. Cardiol. 2013; 61: 1679-85.Hofmann U, Frantz S. How can we cure a heart ‘in flame’? A translational view on inflammation in heart failure. Basic Res Cardiol. 2013; 108: 356. doi:10.1007/s00395-013-0356-y.Hofmann U., Frantz S. How can we cure a heart ‘in flame’? A translational view on inflammation in heart failure. Basic. Res. Cardiol. 2013; 108: 356.Deftereos S, Giannopoulos G, Panagopoulou V, Bouras G, Raisakis K, Kossyvakis C, Karageorgiou S, Papadimitriou C, Vastaki M, Kaoukis A, Angelidis C, Pagoni S, Pyrgakis V, Alexopoulos D, Manolis AS, Stefanadis C, Cleman MW. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014; 2(2): 131-7. doi:10.1016/j.jchf.2013.11.006.Deftereos S., Giannopoulos G., Panagopoulou V. et al. Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014; 2 (2): 131-137.Van Tassell B, Canada J, Arena R, Abbate A. Colchicine in Stable Chronic Heart Failure. JCHF. 2014; 2(5): 538. doi:10.1016/j.jchf.2014.04.009Van Tassell B., Canada J., Arena R., Abbate A. Colchicine in Stable Chronic Heart Failure. JCHF. 2014; 2 (5): 538.

The authors declare that there are no conflicts of interest present.